butalbital ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
hypnotics, barbituric acid derivatives 441 77-26-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alisobumal
  • allylbarbital
  • allylbarbitone
  • allylisobutylbarbital
  • allylisobutylbarbituric acid
  • butalbarbital
  • isobutylallylbarbituric acid
  • itobarbital
  • butalbital
management of butalbital withdrawal can be simplified by using a phenobarbital-loading protocol; RN given refers to parent cpd
  • Molecular weight: 224.26
  • Formula: C11H16N2O3
  • CLOGP: 1.63
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 75.27
  • ALOGS: -2
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3.60 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 22.30 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
May 4, 1976 FDA ACTAVIS LABS UT INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 230.89 15.14 160 6580 145513 63336769
Death 139.28 15.14 184 6556 374197 63108085
Toxicity to various agents 77.30 15.14 112 6628 247138 63235144
Migraine 51.40 15.14 59 6681 103287 63378995
Cholecystitis chronic 48.06 15.14 23 6717 10338 63471944
Drug abuse 38.76 15.14 43 6697 72475 63409807
Cardio-respiratory arrest 31.08 15.14 35 6705 59924 63422358
Peritoneal perforation 30.65 15.14 6 6734 120 63482162
Poisoning 28.76 15.14 18 6722 13682 63468600
Headache 25.99 15.14 134 6606 633107 62849175
Hypoaesthesia 24.79 15.14 55 6685 168338 63313944
Product complaint 22.38 15.14 15 6725 12794 63469488
Breast cyst 21.98 15.14 8 6732 1813 63480469
Drug abuser 21.62 15.14 9 6731 2914 63479368
Injection site necrosis 20.40 15.14 7 6733 1337 63480945
Emotional distress 20.38 15.14 21 6719 32528 63449754
Tracheitis 19.58 15.14 6 6734 801 63481481
Depression 18.31 15.14 54 6686 196438 63285844
Intentional product misuse 18.09 15.14 27 6713 60890 63421392
Dependence 17.43 15.14 7 6733 2070 63480212
Gallbladder disorder 17.23 15.14 15 6725 18827 63463455
Anxiety 15.90 15.14 55 6685 217486 63264796
Injury 15.68 15.14 28 6712 73219 63409063
Off label use 15.63 15.14 30 6710 674432 62807850

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 89.52 26.03 78 870 397971 34558012
Cardio-respiratory arrest 44.33 26.03 24 924 55249 34900734

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 267.04 17.25 253 5145 566261 79172729
Completed suicide 262.98 17.25 178 5220 245589 79493401
Toxicity to various agents 101.28 17.25 133 5265 421407 79317583
Cardio-respiratory arrest 71.52 17.25 59 5339 108451 79630539
Drug abuse 51.26 17.25 59 5339 162632 79576358
Migraine 48.30 17.25 43 5355 87450 79651540
Cholecystitis chronic 45.24 17.25 19 5379 9887 79729103
Peritoneal perforation 31.35 17.25 6 5392 170 79738820
Poisoning 28.48 17.25 19 5379 25253 79713737
Emotional distress 26.85 17.25 22 5376 39947 79699043
Off label use 25.47 17.25 15 5383 907200 78831790
Injection site necrosis 22.84 17.25 7 5391 1471 79737519
Drug abuser 22.43 17.25 10 5388 6003 79732987
Headache 22.07 17.25 95 5303 653677 79085313
Injury 20.90 17.25 26 5372 77470 79661520
Gallbladder disorder 20.50 17.25 14 5384 19326 79719664
Dependence 19.45 17.25 7 5391 2415 79736575
Tracheitis 19.30 17.25 6 5392 1322 79737668

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0002177 Barbiturates
FDA EPC N0000175693 Barbiturate
CHEBI has role CHEBI:35717 hypnotics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tension-type headache indication 398057008
Migraine off-label use 37796009 DOID:6364
Necrotizing enterocolitis in fetus OR newborn contraindication 2707005
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hepatic encephalopathy contraindication 13920009 DOID:13413
Chronic disease of respiratory system contraindication 17097001
Mood swings contraindication 18963009
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Gastrointestinal ulcer contraindication 40845000
Hypothyroidism contraindication 40930008 DOID:1459
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Bradycardia contraindication 48867003
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Poisoning by acetaminophen contraindication 70273001
Agoraphobia contraindication 70691001 DOID:593
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Factor II deficiency contraindication 73975000
Reye's syndrome contraindication 74351001 DOID:14525
Gastrointestinal hemorrhage contraindication 74474003
Urethral stricture contraindication 76618002
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Epilepsy contraindication 84757009 DOID:1826
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hemophilia contraindication 90935002
Anemia due to enzyme deficiency contraindication 111577008
Acute abdominal pain contraindication 116290004
Procedure on urinary system contraindication 118677009
von Willebrand disorder contraindication 128105004 DOID:12531
Seizure disorder contraindication 128613002
Obsessive-compulsive disorder contraindication 191736004 DOID:10933
Insomnia contraindication 193462001
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Benign prostatic hyperplasia contraindication 266569009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Lesion of brain contraindication 301766008
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Panic disorder contraindication 371631005 DOID:594
Primary adrenocortical insufficiency contraindication 373662000
Operation on gastrointestinal tract contraindication 386621005
Pseudomembranous enterocolitis contraindication 397683000
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Myocardial infarction in recovery phase contraindication 418044006
Central nervous system depression contraindication 418072004
Porphyria contraindication 418470004
Ultrarapid metabolizer due to cytochrome p450 CYP2D6 variant contraindication 422681000
Dysfunction of sphincter of Oddi contraindication 430887001
Acute erosive gastritis contraindication 444926003
Acute exacerbation of asthma contraindication 708038006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.65 acidic
pKa2 9.34 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL

External reference:

IDSource
4018107 VUID
N0000179058 NUI
D03182 KEGG_DRUG
19860 RXNORM
C0054234 UMLSCUI
CHEBI:102524 CHEBI
CHEMBL454 ChEMBL_ID
DB00241 DRUGBANK_ID
2481 PUBCHEM_CID
C004470 MESH_SUPPLEMENTAL_RECORD_UI
7138 IUPHAR_LIGAND_ID
7 INN_ID
KHS0AZ4JVK UNII
4311 MMSL
72849 MMSL
d03061 MMSL
387563005 SNOMEDCT_US
96196008 SNOMEDCT_US
4018107 VANDF
001423 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fiorinal with Codeine HUMAN PRESCRIPTION DRUG LABEL 4 0023-6010 CAPSULE 50 mg ORAL NDA 36 sections
Fiorinal HUMAN PRESCRIPTION DRUG LABEL 3 0023-6146 CAPSULE 50 mg ORAL NDA 23 sections
Butalbital, Acetaminophen, Caffeine and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0054-0650 CAPSULE 50 mg ORAL ANDA 33 sections
Butalbital, Acetaminophen, Caffeine and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0054-0650 CAPSULE 50 mg ORAL ANDA 33 sections
Butalbital, Acetaminophen, Caffeine and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0054-3000 CAPSULE 50 mg ORAL ANDA 33 sections
Butalbital, Acetaminophen, Caffeine and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0054-3000 CAPSULE 50 mg ORAL ANDA 33 sections
BUPAP HUMAN PRESCRIPTION DRUG LABEL 2 0095-3000 TABLET 50 mg ORAL ANDA 25 sections
Butalbital, Acetaminophen, and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0143-0170 CAPSULE 50 mg ORAL ANDA 26 sections
Butalbital, Aspirin, Caffeine and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0527-1312 CAPSULE 50 mg ORAL ANDA 25 sections
Butalbital, aspirin, and caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0527-1552 CAPSULE 50 mg ORAL ANDA 25 sections
Butalbital, aspirin, and caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0527-1552 CAPSULE 50 mg ORAL ANDA 25 sections
Butalbital, Acetaminophen, and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0527-1695 TABLET 50 mg ORAL ANDA 27 sections
Butalbital, Acetaminophen, and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0527-1695 TABLET 50 mg ORAL ANDA 27 sections
butalbital, acetaminophen and caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0527-4094 CAPSULE 50 mg ORAL ANDA 27 sections
butalbital, acetaminophen and caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0527-4094 CAPSULE 50 mg ORAL ANDA 27 sections
Butalbital, Acetaminophen, and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0527-4095 CAPSULE 50 mg ORAL ANDA 27 sections
Butalbital, Acetaminophen, and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0527-4095 CAPSULE 50 mg ORAL ANDA 27 sections
Butalbital, Acetaminophen, and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0591-2640 CAPSULE 50 mg ORAL ANDA 25 sections
Butalbital, Acetaminophen, and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0591-2640 CAPSULE 50 mg ORAL ANDA 25 sections
Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0591-2641 CAPSULE 50 mg ORAL ANDA 27 sections
Butalbital, Aspirin, and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0591-3219 CAPSULE 50 mg ORAL NDA authorized generic 24 sections
Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0591-3220 CAPSULE 50 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0591-3220 CAPSULE 50 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0591-3220 CAPSULE 50 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Butalbital, Acetaminophen, and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0591-3369 TABLET 50 mg ORAL ANDA 27 sections
Butalbital, Aspirin, Caffeine and Codeine Phosphate HUMAN PRESCRIPTION DRUG LABEL 4 0591-3546 CAPSULE 50 mg ORAL NDA authorized generic 38 sections
butalbital and acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0603-2540 TABLET 50 mg ORAL ANDA 25 sections
butalbital and acetaminophen HUMAN PRESCRIPTION DRUG LABEL 2 0603-2540 TABLET 50 mg ORAL ANDA 25 sections
Butalbital, Acetaminophen and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0603-2544 TABLET 50 mg ORAL ANDA 27 sections
Butalbital, Acetaminophen and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 0603-2544 TABLET 50 mg ORAL ANDA 27 sections